Voriconazole* is a broad spectrum triazole antifungal agent.
Indication: Used in the treatment of patients with progressive, possibly life-threatening fungal infections such as candidaemia in non-neutropenic patients, invasive candidiasis in skin, abdomen, kidney, bladder wall and wounds, invasive aspergillosis and infections caused by Scedosporium spp and Fusarium spp in patients intolerant/refractory to other therapies. Can be used for prophylaxis in high risk allogeneic hematopoietic stem cell transplant recipients (EU only).
Application: Administered by intravenous infusion.
Presentations |
|
||||||||||||||||||
Dosage form |
Lyophilized vials |
||||||||||||||||||
Strength |
200mg |
||||||||||||||||||
Compliance |
Ph. Eur. USP |
||||||||||||||||||
Manufacturing site |
CMO for Xellia Pharmaceuticals ApS |
||||||||||||||||||
Release site |
CMO for Xellia Pharmaceuticals ApS |
||||||||||||||||||
Site registered |
EU GMP issued by Medicines and Healthcare products Regulatory Agency US FDA Other Health Authorities |
||||||||||||||||||
Batch size |
|
||||||||||||||||||
Regulatory documentation |
EU dossier US dossier RoW* dossier |
||||||||||||||||||
Packaging sizes |
|
||||||||||||||||||
Shelf life |
| ||||||||||||||||||
Storage conditions |
| ||||||||||||||||||
* Products protected by valid patents are not offered for sale in countries, where the sale of such products constitutes a patent infringement.
* * Rest of the world
